NEXUS FPO (ASX: NXS) Share Price and News

Why the Next Science share price is racing higher today

James Mickleboro | December 13, 2019 10:58am

The Next Science Ltd (ASX:NXS) share price is racing higher on Friday after being granted a patent in the United States... More »

Why the Paradigm share price is up 250% in 2019

Tom Richardson | December 10, 2019 1:52pm

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are up from 99 cents on New Year’s day 2019 to $3.49 today and even hit as high... More »

The Next Science share price is tanking on a trading update

Tom Richardson | October 30, 2019 2:46pm

Will Next Science turn into a 'multi bagger' for investors? It alreadsy has four anti-bacterial FDA-approved products used in surgery. More »

Why the Novita Healthcare share price is now up 350% in 3 days

Tom Richardson | October 28, 2019 4:19pm

Novita shows how penny stocks can offfer incredible gains in percentage terms. However, penny stocks are risky. More »

Is Paradigm the real deal blockbuster biotech?

Tom Richardson | October 25, 2019 10:01am

Paradigm is a speculative biotech business exciting investors with news over its Zilosul drug's potential to treat osteoarthritis. More »

Why the Polynovo share price is now up 24x in 5 years

Tom Richardson | October 10, 2019 12:43pm

The Polynovo Ltd (ASX: PNV) share price is up 7% to $2.43 this lunchtime despite the biotech not releasing any specific news to the... More »

Paradigm reports “ground-breaking” osteoarthritis discovery: Is it the real deal?

Tom Richardson | September 30, 2019 9:23am

Paradigm Biopharmaceuticals (ASX:PAR) is looking to partner with big pharma. More »

Is Paradigm Biopharmaceuticals the share market’s next huge winner?

Tom Richardson | September 26, 2019 5:32pm

Paradigm: Buy the rumour, sell the news? More »

Why the Bionomics share price is up 40% today

Tom Richardson | September 26, 2019 4:25pm

Bionomics Ltd (ASX: BNO) looks very speculative. More »

Paradigm share price tanks despite positive clinical trial update

Tom Richardson | September 10, 2019 2:50pm

Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a speccy biotech that could sink or soar. More »

Why the Mesoblast share price is going nuts today

Tom Richardson | September 10, 2019 2:34pm

Mesoblast limited (ASX: MSB) has signed an important partnership with Grünenthal. More »

Why Telix Pharmaceuticals shares are up 80% over the past year

Tom Richardson | August 1, 2019 9:51am

Telix Pharmaceuticals is an oncology researcher with a renal cancer treatment at the Phase III stage. More »

Biotech speccy Paradigm is being tipped for the big time

Tom Richardson | July 31, 2019 3:16pm

Paradigm (ASX: PAR) has $78 million cash on hand and a goal to commercialise osteoarthritis drugs. More »

Why the Next Science share price has more than tripled in 2019

Tom Richardson | July 26, 2019 2:35pm

Next Science (ASX: NXS) and Paradigm (ASX: PAR) are two widely fancied speccy biotechs. More »